Table 1 Summary of TCGA and Mayo Clinic Studies
From: Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer
TCGA (n = 407) | Mayo Clinic (N = 326) | |
|---|---|---|
Time to recurrence/Progression free survival | ||
Median TTR | 15.3 (months) | 13.0 (months) |
No recurrence/No progression | 49.87 (%) | 31.59 (%) |
Recurrence/Progression | 48.40 (%) | 67.79 (%) |
Stage | ||
I | 3.19 (%) | 1.53 (%) |
II | 4.17 (%) | 3.06 (%) |
III or IV | 92.13 (%) | 95.39 (%) |
Age | ||
Mean, [Q1, median, Q3] | 59.8 [53, 60, 68] | 58.3 [50, 55.5, 66.25] |
Surgical debulking | ||
Optimal | 65.11 (%) | 73.92 (%) |
Sub-optimal | 23.83 (%) | 24.84 (%) |